PARP1 and cancer: The use of NQO1-bioactivatable drug (e.g., β-lap) with PARP inhibitors have been shown to significantly expand the clinical application of PARP inhibitors outside of BRCA1/2 mutant cancers for which the majority of PARP inhibitors are currently approved.